ALLO

SEC source: 0001593968-24-000195 · primary_01.xml · derivative · entry 2

Parker Geoffrey M. · CIK 0001491874 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 103,939

Underlying: Common Stock · 103,939 shares

Expires 2034-01-25

F1 · derivative.exercise_date: 1/3 of the shares subject to the stock option shall vest on January 25, 2025, and the remaining shares shall vest in 24 equal monthly installments thereafter.

SEC source: 0001593968-24-000195 · primary_01.xml · nonDerivative · entry 1

Parker Geoffrey M. · CIK 0001491874 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 819,400

SEC source: 0001593968-24-000194 · primary_01.xml · derivative · entry 5

Belldegrun Arie · CIK 0001296549 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 749,398

Underlying: Common Stock · 749,398 shares

Expires 2034-01-25

F4 · derivative.exercise_date: 1/3 of the shares subject to the stock option shall vest on January 25, 2025, and the remaining shares shall vest in 24 equal monthly installments thereafter.

SEC source: 0001593968-24-000194 · primary_01.xml · nonDerivative · entry 1

Belldegrun Arie · CIK 0001296549 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,866,859

SEC source: 0001593968-24-000196 · primary_01.xml · derivative · entry 2

Douglas Earl Martin · CIK 0001362155 · SVP, General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 147,778

Underlying: Common Stock · 147,778 shares

Expires 2034-01-25

F1 · derivative.exercise_date: 1/3 of the shares subject to the stock option shall vest on January 25, 2025, and the remaining shares shall vest in 24 equal monthly installments thereafter.

SEC source: 0001593968-24-000196 · primary_01.xml · nonDerivative · entry 1

Douglas Earl Martin · CIK 0001362155 · SVP, General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 477,634

SEC source: 0001593968-24-000192 · primary_01.xml · derivative · entry 5

Chang David D · CIK 0001611024 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,123,535

Underlying: Common Stock · 1,123,535 shares

Expires 2034-01-25

F5 · derivative.exercise_date: 1/3 of the shares subject to the stock option shall vest on January 25, 2025, and the remaining shares shall vest in 24 equal monthly installments thereafter.

SEC source: 0001593968-24-000192 · primary_01.xml · nonDerivative · entry 1

Chang David D · CIK 0001611024 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,513,203

F1 · balance_after: Includes 1492 shares of the Issuer's common stock acquired by the reporting person on September 15,2023 pursuant to an employee stock purchase program.

SEC source: 0001593968-24-000142 · primary_01.xml · nonDerivative · entry 1

Roberts Zachary · CIK 0001851044 · EVP of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 375,253

F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.15 to $3.205, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001593968-23-001520 · primary_01.xml · nonDerivative · entry 1

MESSEMER DEBORAH M. · CIK 0001754424 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 62,456

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 06/29/2023

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.62 to $2.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001593968-23-001369 · primary_01.xml · derivative · entry 3

Parker Geoffrey M. · CIK 0001491874 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 950,000

Underlying: Common Stock · 950,000 shares

Expires 2033-10-16

F2 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on October 16, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.

SEC source: 0001593968-23-001369 · primary_01.xml · nonDerivative · entry 2

Parker Geoffrey M. · CIK 0001491874 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 790,000

F1 · acquired: Constitutes Performance Restricted Stock Units ("PRSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each PRSU upon vesting, 50% shall vest in the event the Company achieves a 30-day weighted average share price of $18 on or before March 22, 2026 and 50% shall vest upon the first marketing approval of a Company product by the US FDA on or before March 22, 2028.

SEC source: 0001593968-23-001369 · primary_01.xml · nonDerivative · entry 1

Parker Geoffrey M. · CIK 0001491874 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 400,000

SEC source: 0001593968-23-001226 · primary_01.xml · derivative · entry 3

Douglas Earl Martin · CIK 0001362155 · GENERAL COUNSEL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 960,854

Underlying: Common Stock · 960,854 shares

Expires 2033-08-14

F2 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on August 14, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.

SEC source: 0001593968-23-001226 · primary_01.xml · nonDerivative · entry 2

Douglas Earl Martin · CIK 0001362155 · GENERAL COUNSEL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 435,834

SEC source: 0001593968-23-001226 · primary_01.xml · nonDerivative · entry 1

Douglas Earl Martin · CIK 0001362155 · GENERAL COUNSEL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,958

F1 · shares: Constitutes Performance Restricted Stock Units ("PRSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each PRSU upon vesting, 50% shall vest in the event the Company achieves a 30-day weighted average share price of $18 on or before March 22, 2026 and 50% shall vest upon the first marketing approval of a Company product by the US FDA on or before March 22, 2028.

SEC source: 0001593968-23-001182 · primary_01.xml · derivative · entry 2

CHEN YINLIN JACK · CIK 0001989926 · SVP, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,160

Underlying: Common Stock · 39,160 shares

Expires 2033-08-10

F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on August 10, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.

SEC source: 0001593968-23-001182 · primary_01.xml · nonDerivative · entry 1

CHEN YINLIN JACK · CIK 0001989926 · SVP, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,881

SEC source: 0001593968-23-001153 · primary_01.xml · nonDerivative · entry 1

Mayo Stephen · CIK 0001849061 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,328

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.27 to $4.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001593968-23-001007 · primary_01.xml · derivative · entry 1

Kazam Joshua A · CIK 0001221355 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,120

Underlying: Common Stock · 116,120 shares

Expires 2033-06-13

F1 · derivative.exercise_date: Vesting in 12 equal monthly installments

SEC source: 0001593968-23-001011 · primary_01.xml · derivative · entry 2

SATO VICKI L · CIK 0001197020 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,224

Underlying: Common Stock · 23,224 shares

Expires 2033-06-13

F1 · derivative.exercise_date: Vesting in 12 equal monthly installments

SEC source: 0001593968-23-001011 · primary_01.xml · nonDerivative · entry 1

SATO VICKI L · CIK 0001197020 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,100

SEC source: 0001593968-23-001010 · primary_01.xml · nonDerivative · entry 1

Humer Franz B · CIK 0001548072 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 266,453

SEC source: 0001593968-23-001009 · primary_01.xml · nonDerivative · entry 1

WITTE OWEN N. · CIK 0001700969 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 292,832

SEC source: 0001593968-23-001013 · primary_01.xml · nonDerivative · entry 1

MESSEMER DEBORAH M. · CIK 0001754424 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,096

SEC source: 0001593968-23-001012 · primary_01.xml · derivative · entry 1

Barrett Elizabeth A. · CIK 0001764157 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,120

Underlying: Common Stock · 116,120 shares

Expires 2033-06-13

F1 · derivative.exercise_date: Vesting in 12 equal monthly installments

SEC source: 0001593968-23-001008 · primary_01.xml · derivative · entry 1

Mayo Stephen · CIK 0001849061 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,120

Underlying: Common Stock · 116,120 shares

Expires 2033-06-13

F1 · derivative.exercise_date: Vesting in 12 equal monthly installments

SEC source: 0001593968-23-000643 · primary_01.xml · derivative · entry 2

MOORE TIMOTHY L. · CIK 0001669207 · Chief Technical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 831,024

Underlying: Common Stock · 831,024 shares

Expires 2033-04-24

F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on April 24, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.

SEC source: 0001593968-23-000643 · primary_01.xml · nonDerivative · entry 1

MOORE TIMOTHY L. · CIK 0001669207 · Chief Technical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 186,219

SEC source: 0001593968-23-000583 · primary_01.xml · nonDerivative · entry 1

Smith Lillian · CIK 0001971448 · VP, Corporate Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,390

F1 · shares: Represents performance RSUs which shall vest as follows: (1) 33% shall vest if the 30-day weighted average stock price is equal to or greater than $18 and (2) 67% shall vest upon the first regulatory approval of a product candidate. Notwithstanding the foregoing (1) any portion that vests upon the stock price threshold shall no longer vest and be terminated on March 22nd, 2026 if such threshold has not been met, and (2) any portion that vests upon product candidate approval shall no longer vest and be terminated after March 22nd, 2028 if such approval has not occurred.

SEC source: 0001593968-23-000525 · primary_01.xml · nonDerivative · entry 1

Roberts Zachary · CIK 0001851044 · EVP of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 399,943

F1 · shares: Represents performance RSUs which shall vest as follows: (1) 33% shall vest if the 30-day weighted average stock price is equal to or greater than $18 and (2) 67% shall vest upon the first regulatory approval of a product candidate. Notwithstanding the foregoing (1) any portion that vests upon the stock price threshold shall no longer vest and be terminated after three years from the grant date if such threshold has not been met in such three-year period, and (2) any portion that vests upon product candidate approval shall no longer vest and be terminated after five years from the grant date if such approval has not occurred in such five-year period.

SEC source: 0001593968-23-000523 · primary_01.xml · derivative · entry 5

Belldegrun Arie · CIK 0001296549 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 994,800

Underlying: Common Stock · 994,800 shares

Expires 2033-03-22

F5 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on March 13, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.

SEC source: 0001593968-23-000523 · primary_01.xml · nonDerivative · entry 1

Belldegrun Arie · CIK 0001296549 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,654,886

F1 · shares: Includes 986,905 of performance RSUs which shall vest as follows: (1) 50% shall vest if the 30-day weighted average stock price is equal to or greater than $18 and (2) 50% shall vest upon the first regulatory approval of a product candidate. Notwithstanding the foregoing (1) any portion that vests upon the stock price threshold shall no longer vest and be terminated after three years from the grant date if such threshold has not been met in such three-year period, and (2) any portion that vests upon product candidate approval shall no longer vest and be terminated after five years from the grant date if such approval has not occurred in such five-year period.

SEC source: 0001593968-23-000521 · primary_01.xml · derivative · entry 5

Chang David D · CIK 0001611024 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,492,200

Underlying: Common Stock · 1,492,200 shares

Expires 2033-03-22

F5 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on March 13, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.

SEC source: 0001593968-23-000521 · primary_01.xml · nonDerivative · entry 1

Chang David D · CIK 0001611024 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,193,911

F1 · shares: Includes 1,480,357 of performance RSUs which shall vest as follows: (1) 50% shall vest if the 30-day weighted average stock price is equal to or greater than $18 and (2) 50% shall vest upon the first regulatory approval of a product candidate. Notwithstanding the foregoing (1) any portion that vests upon the stock price threshold shall no longer vest and be terminated after three years from the grant date if such threshold has not been met in such three-year period, and (2) any portion that vests upon product candidate approval shall no longer vest and be terminated after five years from the grant date if such approval has not occurred in such five-year period.

SEC source: 0001593968-23-000529 · primary_01.xml · derivative · entry 2

MOORE ALISON · CIK 0001754937 · Chief Technical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 432,738

Underlying: Common Stock · 432,738 shares

Expires 2033-03-22

F2 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on March 13, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.

SEC source: 0001593968-23-000529 · primary_01.xml · nonDerivative · entry 1

MOORE ALISON · CIK 0001754937 · Chief Technical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 672,731

F1 · shares: Includes 429,303 of performance RSUs which shall vest as follows: (1) 33% shall vest if the 30-day weighted average stock price is equal to or greater than $18 and (2) 67% shall vest upon the first regulatory approval of a product candidate. Notwithstanding the foregoing (1) any portion that vests upon the stock price threshold shall no longer vest and be terminated after three years from the grant date if such threshold has not been met in such three-year period, and (2) any portion that vests upon product candidate approval shall no longer vest and be terminated after five years from the grant date if such approval has not occurred in such five-year period.

SEC source: 0001593968-23-000527 · primary_01.xml · derivative · entry 3

SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 432,738

Underlying: Common Stock · 432,738 shares

Expires 2033-03-22

F3 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on March 13, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.

SEC source: 0001593968-23-000527 · primary_01.xml · nonDerivative · entry 1

SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 862,439

F1 · shares: Includes 429,303 of performance RSUs which shall vest as follows: (1) 50% shall vest if the 30-day weighted average stock price is equal to or greater than $18 and (2) 50% shall vest upon the first regulatory approval of a product candidate. Notwithstanding the foregoing (1) any portion that vests upon the stock price threshold shall no longer vest and be terminated after three years from the grant date if such threshold has not been met in such three-year period, and (2) any portion that vests upon product candidate approval shall no longer vest and be terminated after five years from the grant date if such approval has not occurred in such five-year period.

SEC source: 0001593968-23-000491 · primary_01.xml · nonDerivative · entry 1

Bhavnagri Veer · CIK 0001808980 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 556,049

F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Includes 2,000 shares of the Issuer's common stock acquired by the reporting person on March 15, 2023 pursuant to an employee stock purchase program.

SEC source: 0001737287-23-000025 · primary_doc.xml · nonDerivative · entry 1

Chang David D · CIK 0001611024 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,269,447

F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.49 to $5.595, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F3 · balance_after: Includes 135 and 2000 share of the Issuer's common stock acquired by the reporting person on September 15, 2021 and on March 15, 2023 pursuant to an employee stock purchase program, respectively.

SEC source: 0001737287-23-000024 · primary_doc.xml · nonDerivative · entry 1

SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 304,345

F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.46 to $5.495, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F3 · balance_after: Includes 320 and 2000 share of the Issuer's common stock acquired by the reporting person on September 15, 2021 and on March 15, 2023 pursuant to an employee stock purchase program, respectively.

SEC source: 0001593968-23-000492 · primary_01.xml · nonDerivative · entry 1

MOORE ALISON · CIK 0001754937 · Chief Technical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,637

F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.49 to $5.515, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F3 · balance_after: Includes 558 and 2000 share of the Issuer's common stock acquired by the reporting person on September 15, 2021 and on March 15, 2023 pursuant to an employee stock purchase program, respectively.

SEC source: 0001593968-23-000317 · primary_01.xml · nonDerivative · entry 1

Bhavnagri Veer · CIK 0001808980 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 577,677

F1 · acquired: 1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in May 2022.

SEC source: 0001737287-23-000004 · primary_doc.xml · derivative · entry 2

Roberts Zachary · CIK 0001851044 · EVP of R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 873,015

Underlying: Common Stock · 873,015 shares

Expires 2033-01-20

F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on January 03, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.

SEC source: 0001737287-23-000004 · primary_doc.xml · nonDerivative · entry 1

Roberts Zachary · CIK 0001851044 · EVP of R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 251,908

SEC source: 0001593968-23-000168 · primary_01.xml · nonDerivative · entry 1

Bhavnagri Veer · CIK 0001808980 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 580,677

F1 · shares: 1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in May 2022.

SEC source: 0001593968-22-001742 · primary_01.xml · nonDerivative · entry 1

Bhavnagri Veer · CIK 0001808980 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 583,677

F1 · shares: 1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in May 2022.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.39 to $7.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001593968-22-001505 · primary_01.xml · nonDerivative · entry 2

Amado Rafael · CIK 0001662119 · EVP of R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 541,946

F2 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.7081 to $11.845, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001593968-22-001505 · primary_01.xml · nonDerivative · entry 1

Amado Rafael · CIK 0001662119 · EVP of R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 550,410

F1 · shares: Represents the vesting of performance-based restricted stock units (Performance RSUs) granted on September 3, 2019. Performance RSUs vested upon the initiation of a Phase 2 clinical trial of ALLO-501A. Each Performance RSU represents the right to receive one share of common stock of the Issuer.